Guardant Health, Inc.
Guardant Health, Inc. (GH) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GH · as of Jun 8, 2026
Key Statistics
Explore Guardant Health, Inc. Data
gh stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 30 · Buy rate: 96.7%
The GH analyst consensus is Buy, based on ratings from 30 Wall Street analysts over the past 3 months. The average 12-month price target is $142.93, representing +13.77% upside from the current price of $125.63.
Competitors & Peers
gh competitorsGH
ASND
BBIO
EHC
EXAS
ICLRStock Performance
Full HistoryAbout Guardant Health, Inc.
Guardant Health, Inc. established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytic…
what is guardant health, inc. · gh stock overview · guardant health, inc. company profile · who is guardant health, inc. ceo · gh NASDAQ · guardant health, inc. headquarters · guardant health, inc. business segments
About Stock Overview & Key Data
Guardant Health, Inc. (GH) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on NASDAQ since Oct 4, 2018. As of the latest trading session, GH stock price is $125.63, with a market capitalization of $16.7B. The stock has returned +158.43% over the past 12 months and +25.32% year-to-date.
According to 30 Wall Street analysts, the consensus rating for Guardant Health, Inc. stock is Buy, with an average 12-month price target of $142.93. In fiscal year 2025, Guardant Health, Inc. reported revenue of $982.0M and net income of -$416.3M. For detailed data — including Guardant Health, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Guardant Health, Inc. (GH) stock price is $125.63. The stock is traded on NASDAQ under the ticker symbol GH. The 52-week range is $40.35 – $133.97.